Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · STATUTE-COMPILATIONS · Patient Protection and Affordable Care Act · Sec. 3507

Sec. 3507. PRESENTATION OF PRESCRIPTION DRUG BENEFIT AND RISK INFORMATION

303 words·~1 min read·/statute-compilations/comps-9307/sec-3507

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

## SEC. 3507 PRESENTATION OF PRESCRIPTION DRUG BENEFIT AND RISK INFORMATION **[**[21 U.S.C. 352 note](/us/usc/t21/s352)**]** ###
(a)In General The Secretary of Health and Human Services (referred to in this section as the “Secretary”), acting through the Commissioner of Food and Drugs, shall determine whether the addition of quantitative summaries of the benefits and risks of prescription drugs in a standardized format (such as a table or drug facts box) to the promotional labeling or print advertising of such drugs would improve health care decisionmaking by clinicians and patients and consumers. ###
(b)Review and Consultation In making the determination under subsection (a), the Secretary shall review all available scientific evidence and research on decisionmaking and social and cognitive psychology and consult with drug manufacturers, clinicians, patients and consumers, experts in health literacy, representatives of racial and ethnic minorities, and experts in women's and pediatric health. ###
(c)Report Not later than 1 year after the date of enactment of this Act, the Secretary shall submit to Congress a report that provides— ####
(1)the determination by the Secretary under subsection (a); and ####
(2)the reasoning and analysis underlying that determination. ###
(d)Authority If the Secretary determines under subsection
(a)that the addition of quantitative summaries of the benefits and risks of prescription drugs in a standardized format (such as a table or drug facts box) to the promotional labeling or print advertising of such drugs would improve health care decisionmaking by clinicians and patients and consumers, then the Secretary, not later than 3 years after the date of submission of the report under subsection (c), shall promulgate proposed regulations as necessary to implement such format. ###
(e)Clarification Nothing in this section shall be construed to restrict the existing authorities of the Secretary with respect to benefit and risk information.
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Sec. 3507
PRESENTATION OF PRESCRIPTION DRUG BENEFIT AND RISK INFORMATION
Cites 1Cited by 0 across 0 sources
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.